|
Lifecare Innovations has been jointly promoted by
Dr Jitendra N. Verma, Founder & Managing Director, Lifecare Innovations (P) Ltd.
Dr Lily Verma, Medical Director, Lifecare Innovations (P) Ltd.
Ms. Arshia A. Lalljee, Finance Director, Lifecare Innovations (P) Ltd.
Mr. Iskander A. Lalljee, Marketing Director, Lifecare Innovations (P) Ltd.
Mrs. Hamida A. Lalljee, Director, Lifecare Innovations (P) Ltd.
Prof. G. K. Khuller, Director Research, Lifecare Innovations (P) Ltd.
Dr. Savita Verma Nigam, Director (Research & Business Coordination, North America),
Lifecare Innovations (P) Ltd.
Dr. Nalini Vemuri, Vice President (R & D), Lifecare Innovations (P) Ltd.
Dr Ranjana K Seth Co-ordinator Clinical Research, Lifecare Innovations (P) Ltd.
Dr Satish Bajpai Vice President (Corporate Affairs), Lifecare Innovations (P) Ltd.
 |
Dr Jitendra N Verma
Founder & Managing Director
Academician, Scientist and Industrialist, Dr Jitendra N Verma is the Founder Managing Director of Lifecare Innovations. An MSc from Allahabad University and PhD from PGIMER, |
| Chandigarh, he has 34 years of academic and industrial research experience. Dr Verma was engaged in medical research at University of Pennsylvania, Northwestern University, Georgetown University and Walter Reed Army Institute of Research in USA. Known for his expertise in Life Sciences & Biotechnology, Dr Verma was acclaimed for promotion of R&D and commercializing their outcome by industry-academia interactions and public-private partnerships. Dr Verma has pioneered development of NDDS based Liposomal and Nano-Drugs. As a leader in Liposome technology application for drugs, diagnostics and vaccines, Dr Verma developed and commercialized India's first Liposomal product and world's only liposomal diagnostic -Liposome agglutination test for Syphilis. He has contributed to Asia's first and world's best anti-fungal drug FUNGISOME - a Liposomal Amphotericin B. Working on malaria vaccine Dr Verma was the first to report that Liposomal vaccines elicit cellular immune response necessary for protective immunity. Dr Verma is presently involved in developing Liposomal and Nano-Drugs for treatment of Tuberculosis, Cancer, Leishmaniasis and Fungal infections. Keenly involved in translational research for taking benefits of Science & Technology by applications in everyday life, Dr Verma has a number of publications, reviews and patents to his credit. He is conferred with the title of Vigyan Ratna and is the recipient of national, international and state awards & honors.
|
 |
Dr. Lily Verma
Medical Director
General Surgeon (MBBS, MS), Medical Research at Georgetown University, USA. Her research |
| areas include Liposomal & Nano drug formulations development, clinical trials and evaluation of Controlled Release Pharmaceuticals for inclusion in Lifecare's product portfolio; embryonic cell research with focus on drug mediated / cultured embryonic cells induced recovery of spinal cord. She heads the Clinical Research, Medical Education & Intellectual Property Management of the company. |
 |
Ms. Arshia A. Lalljee
Finance Director
Has a Masters degree in Sociology from Jawaharlal Nehru University and MPhil in Business Management from Leeds University, UK. She has rich and varied experience in Finance & |
| Accounts Management, Banking, Corporate Affairs, Investment Management and General Administration. |
 |
Mr. Iskander A. Lalljee
Marketing Director
Is experienced in niche marketing. His expertise covers Marketing Research, Product Development and New Product Launch. Mr Lalljee has special interest in pollution control. His |
| efforts have also contributed to the development of eco-friendly devices aimed at minimizing health hazards. |
 |
Mrs. Hamida A. Lalljee
Director
As Executive Director of Sud-Chemie India Pvt. Ltd. has industrial and administrative experience .
|
 |
Prof. G. K. Khuller
Director Research
Concurrently Emeritus Professor is former Head, Biochemistry, and Emeritus Scientist CSIR at PGIMER, Chandigarh. His research interests include development of nanotechnology based |
| sustained release drug delivery formulations for antitubercular and other drugs; biochemical and immunochemical studies of mycobacteria; biochemical mechanism of drug resistance; identification of new drug targets for antimycobacterial drugs; and regulation of lipid metabolism by second messengers. He is recipient of several awards like the Young Scientist Award of ICMR in 1983, Dr S Gopalakrishnan Oration of ACBI in 1996, Seth G S Medical College Oration of ACBI in 1997, Fellow of ACBI in 1998 and Dr G P Talwar Oration of ACBI in 2004. He is a Member of American Society of Nanotechnology and of Indian Delegation for Nano-initiative research program of DST between India, Brazil & South Africa (IBSA). He has several patents, has published about 300 research papers and authored several book chapters. |
 |
Dr. Savita Verma Nigam
Director (Research & Business Coordination, North America)
Has directed Hematomimetics Program (HMP Biochemistry) section at the Naval Medical research Centre (NMRC) in Operational and Undersea Medicine Directorate for basic and |
| clinical research program. She has also worked on developing vasoactive hemoglobin based oxygen carrier (VA-HBOC) for the treatments to further attenuate pulmonary and systemic hypertension and minimize the methemoglobinemia in casualties resuscitated in the pre-hospital setting with vasoactive hemoglobin based oxygen carrier (VA-HBOC).As a Principal Investigator, she has provided leadership for the development, qualification and validation of biochemical methods to support chemical defense projects for the development, design, evaluation, and optimize bio-analytical test methods for protein biomarkers and also evaluated catalytic bioscavenger to reduce the in vivo toxicity of chemical warfare OP nerve agents (CWNAs). |
 |
Dr. Nalini Vemuri
Vice President (R & D)
An MSc from Pune University, & PhD from PGIMER, Chandigarh where she received an award |
| for her research on glycolipids of Mycobacterium tuberculosis. Continuing her interest, she worked on Phenolic glycolipids & cell wall antigens of Mycobacterium leprae with Prof Patrick Brennan at Colorado State University, USA; at Foundation for Medical Research, Mumbai; and National Institute of Immunology & AIIMS, New Delhi. Prior to Lifecare Innovations Dr Vemuri was an Associate Professor of Biotechnology & Cordinator of the Pharmacy Program at JIIT University. She has more than 28 years of research experience in Mycobacterial diseases & possesses expertise in host-pathogen interactions, immunodiagnostics & tissue culture engineering. |
 |
Dr Ranjana K Seth
Co-ordinator Clinical Research
MSc in Biochemistry from Lucknow University & PhD from CDRI, Lucknow, she has expertise in Biochemical Pharmacology, Molecular & Developmental Biology & worked at University of |
| Illinois at Chicago (UIC) & National Institutes of Health (NIH), USA. At UIC, Dr Seth has worked with post-mortem brain samples from patients of psychiatric disorders for studies on involvement of serotonergic system in depression & suicide and at NIH Bethesda, she has carried out investigations into molecular aspects of 12(S)HETE-dependent activation of PKC in lens epithelial cells.
Dr Seth has several research papers & scientific reviews to her credit. |
| |
|
 |
Dr Satish Bajpai
Vice President (Corporate Affairs)
He is a Chartered Accountant with a PhD in Finance. Dr Bajpai is a corporate generalist with expertise in early stage start-ups and focus on profit centres through robust strategy and |
| processes. His experience comprises of business analysis for viability and expansion, vetting of financial proposals, financial negotiations, compliances & audit. |
|
|
